NCT06348576
Recruiting
Phase 3
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
ConditionsHypertension,Essential
Overview
- Phase
- Phase 3
- Intervention
- AD-209
- Conditions
- Hypertension,Essential
- Sponsor
- Addpharma Inc.
- Enrollment
- 280
- Locations
- 1
- Primary Endpoint
- Change rate of MSSBP
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-209
Detailed Description
Condition or disease : hypertension
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent
- •Other inclusions applied
Exclusion Criteria
- •Orthostatic hypotension with symptom
- •Other exclusions applied
Arms & Interventions
Test group
AD-209+AD-2091 Placebo
Intervention: AD-209
Test group
AD-209+AD-2091 Placebo
Intervention: AD-2091 Placebo
Control group
AD-2091+AD-209 Placebo
Intervention: AD-2091
Control group
AD-2091+AD-209 Placebo
Intervention: AD-209 Placebo
Outcomes
Primary Outcomes
Change rate of MSSBP
Time Frame: Baseline, Week 8
Change from baseline in mean sitting systolic blood pressure
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of AD-209Hypertension, EssentialNCT05631990Addpharma Inc.221
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of AD-223Hypertension,EssentialNCT06052748Addpharma Inc.502
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of AD-224Hypertension,EssentialNCT06291207Addpharma Inc.252
Completed
Phase 2
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)Viral ConjunctivitisNCT01977443Adenovir Pharma AB47
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of AD-218Mixed DyslipidemiaNCT05400317Addpharma Inc.520